py (AIT) andNuance Pharma’sprovenexpertise in market access as well as their established commercial platform in China, we aim to accelerate access to Actair®for patients in need. This major step forward underscores Stallergenes Greer’s determination to provide valuable evidence-based treatment options for individuals suffering from house-dust mite allergies. It also supports our broader ambition to expand the availability of our AIT treatments across more geographies, while unlocking the full potential of Actair®,”stated Dr Andreas Amrein, CEO of Stallergenes Greer.

“Respiratory disease is among Nuance's core areas of focus, and we are actively building a franchise with innovative solutions. Actair®is a perfect fit for our portfolio and strategy, as it represents a differentiated solution to address the medical needs in allergy. We look forward to a successful partnership with Stallergenes Greer, a leader in allergy therapeutics, on Act
=*=*=*=*=*=
当前为第2/6页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页